Balancing trained immunity with persistent immune activation and the risk of simian immunodeficiency virus infection in infant macaques vaccinated with attenuated mycobacterium tuberculosis or mycobacterium bovis BCG vaccine

Clinical and Vaccine Immunology

Volumn 24, Issue 1, 2017, Pages

  Jensen, Kara ^a   Dela Pena Ponce, Myra Grace ^a   Piatak, Michael ^b   Shoemaker, Rebecca ^b   Oswald, Kelli ^b   Jacobs, William R ^c   Fennelly, Glenn ^d   Lucero, Carissa ^b   Mollan, Katie R ^e   Hudgens, Michael G ^f   Amedee, Angela ^g   Kozlowski, Pamela A ^g   Estes, Jacob D ^b   Lifson, Jeffrey D ^b   Van Rompay, Koen K A ^h   Larsen, Michelle ^c   De Paris, Kristina ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f University of North Carolina at Chapel Hill   (United States)

^g LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immune activation; Myeloid cells; Pediatric HIV SIV; Vaccine

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; BCG VACCINE; CD14 ANTIGEN; CD16 ANTIGEN; CD163 ANTIGEN; CD69 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CLAUDIN 3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 6; INTERLEUKIN 8; KI 67 ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; PROGRAMMED DEATH 1 RECEPTOR; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR; VACCINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCG VACCINATION; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; GASTROINTESTINAL TISSUE; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOREACTIVITY; INFANT; INNATE IMMUNITY; MACACA; MACROPHAGE; MALE; MONOCYTE; MOUTH TISSUE; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; ANIMAL; DRUG INTERACTION; IMMUNOLOGY; RHESUS MONKEY; TREATMENT OUTCOME;

ANIMALS; DRUG INTERACTIONS; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, COMBINED;

EID: 85011298617     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.0036016     Document Type: Article

References (96)

1. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698-702.
2. Rodrigues LC, Diwan VK, Wheeler JG. 1993. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 22:1154-1158. https://doi.org/10.1093/ije/22.6.1154.
3. Trunz BB, Fine P, Dye C. 2006. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a metaanalysis and assessment of cost-effectiveness. Lancet 367:1173-1180. https://doi.org/10.1016/S0140-6736(06)68507-3.
4. Hesseling AC, Marais BJ, Gie RP, Schaaf HS, Fine PE, Godfrey-Faussett P, Beyers N. 2007. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 25:14-18. https://doi.org/ 10.1016/j.vaccine.2006.07.020.
5. Larsen MH, Biermann K, Chen B, Hsu T, Sambandamurthy VK, Lackner AA, Aye PP, Didier P, Huang D, Shao L, Wei H, Letvin NL, Frothingham R, Haynes BF, Chen ZW, Jacobs WR, Jr. 2009. Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine 27:4709-4717. https://doi.org/10.1016/j.vaccine.2009.05.050.
6. Larsen MH, Jacobs WR, Porcelli SA, Kim J, Ranganathan UD, Fennelly GJ. 2010. Balancing safety and immunogenicity in live-attenuated mycobacterial vaccines for use in humans at risk for HIV: response to misleading comments in Ranganathan et al. "Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. Tuberculosis in neonatal mice." Vaccine 28:3633-3634. https://doi.org/10.1016/j.vaccine .2010.03.025.
7. Ranganathan UD, Larsen MH, Kim J, Porcelli SA, Jacobs WR, Jr, Fennelly GJ. 2009. Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. Tuberculosis in neonatal mice. Vaccine 28:152-161. https://doi.org/10.1016/j.vaccine.2009.09.087.
8. Jensen K, Ranganathan UD, Van Rompay KK, Canfield DR, Khan I, Ravindran R, Luciw PA, Jacobs WR, Jr, Fennelly G, Larsen MH, Abel K. 2012. A recombinant attenuated Mycobacterium tuberculosis vaccine strain is safe in immunosuppressed simian immunodeficiency virus-infected infant macaques. Clin Vaccine Immunol 19:1170-1181. https://doi.org/ 10.1128/CVI.00184-12.
9. Jensen K, Nabi R, Van Rompay KK, Robichaux S, Lifson JD, Piatak M, Jr, Jacobs WR, Jr, Fennelly G, Canfield D, Mollan KR, Hudgens MG, Larsen MH, Amedee AM, Kozlowski PA, De Paris K. 2016. Vaccine-elicited mucosal and systemic antibody responses are associated with reduced simian immunodeficiency viremia in infant rhesus macaques. J Virol 90:7285-7302. https://doi.org/10.1128/JVI.00481-16.
10. Jensen K, Pena MG, Wilson RL, Ranganathan UD, Jacobs WR, Jr, Fennelly G, Larsen M, Van Rompay KK, Kozlowski PA, Abel K. 2013. A neonatal oral Mycobacterium tuberculosis-SIV prime/intramuscular MVA-SIV boost combination vaccine induces both SIV and TB-specific immune responses in infant macaques. Trials Vaccinol 2:53-63. https//doi.org/ 10.1016/j.trivac.2013.09.005.
11. Hesseling AC, Caldwell J, Cotton MF, Eley BS, Jaspan HB, Jennings K, Marais BJ, Nuttall J, Rabie H, Roux P, Schaaf HS. 2009. BCG vaccination in South African HIV-exposed infants-risks and benefits. S Afr Med J 99:88-91.
12. Hesseling AK, Passmore J-AS, Gamieldien H, Jones CE, Hanekom W, Sodora DL, Jaspan HB. 2012. BCG vaccination at birth induces nonspecific CD4+T cell activation in HIV-exposed South African infants which may increase HIV transmission through breastfeeding, abstr FRLBC04. XIX International AIDS Conference, Washington, DC.
13. Libraty DH, Zhang L, Woda M, Acosta LP, Obcena A, Brion JD, Capeding RZ. 2014. Neonatal BCG vaccination is associated with enhanced T-helper 1 immune responses to heterologous infant vaccines. Trials Vaccinol 3:1-5. https://doi.org/10.1016/j.trivac.2013.11.004.
14. Ota MO, Vekemans J, Schlegel-Haueter SE, Fielding K, Sanneh M, Kidd M, Newport MJ, Aaby P, Whittle H, Lambert PH, McAdam KP, Siegrist CA, Marchant A. 2002. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol 168:919-925. https://doi.org/10.4049/jimmunol .168.2.919.
15. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, Jacobs C, van Loenhout J, de Jong D, Stunnenberg HG, Xavier RJ, van der Meer JW, van Crevel R, Netea MG. 2012. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A 109: 17537-17542. https://doi.org/10.1073/pnas.1202870109.
16. Kleinnijenhuis J, Quintin J, Preijers F, Benn CS, Joosten LA, Jacobs C, van Loenhout J, Xavier RJ, Aaby P, van der Meer JW, van Crevel R, Netea MG. 2014. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate Immun 6:152-158. https://doi.org/10.1159/000355628.
17. Cayabyab MJ, Hovav AH, Hsu T, Krivulka GR, Lifton MA, Gorgone DA, Fennelly GJ, Haynes BF, Jacobs WR, Jr, Letvin NL. 2006. Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. J Virol 80:1645-1652. https://doi.org/10.1128/ JVI.80.4.1645-1652.2006.
18. Hopkins R, Bridgeman A, Bourne C, Mbewe-Mvula A, Sadoff JC, Both GW, Joseph J, Fulkerson J, Hanke T. 2011. Optimizing HIV-1-specific CD8(+) T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. Eur J Immunol 41:3542-3552. https://doi.org/ 10.1002/eji.201141962.
19. Im EJ, Saubi N, Virgili G, Sander C, Teoh D, Gatell JM, McShane H, Joseph J, Hanke T. 2007. Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J Virol 81:9408-9418. https://doi.org/10.1128/ JVI.00707-07.
20. Saubi N, Im EJ, Fernandez-Lloris R, Gil O, Cardona PJ, Gatell JM, Hanke T, Joseph J. 2011. Newborn mice vaccination with BCG.HIVA(2)(2)(2)-MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes. Clin Dev Immunol 2011:516219. https:// doi.org/10.1155/2011/516219.
21. Sampson SL, Mansfield KG, Carville A, Magee DM, Quitugua T, Howerth EW, Bloom BR, Hondalus MK. 2011. Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate. Vaccine 29: 4839-4847. https://doi.org/10.1016/j.vaccine.2011.04.066.
22. Aldovini A, Young RA. 1991. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 351:479-482. https://doi.org/10.1038/351479a0.
23. Chapman R, Shephard E, Stutz H, Douglass N, Sambandamurthy V, Garcia I, Ryffel B, Jacobs W, Williamson AL. 2012. Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells. PLoS One 7:e32769. https://doi.org/10.1371/journal.pone.0032769.
24. Chapman R, Stutz H, Jacobs W, Jr, Shephard E, Williamson AL. 2013. Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice. PLoS One 8:e71601. https://doi.org/10.1371/ journal.pone.0071601.
25. Someya K, Cecilia D, Ami Y, Nakasone T, Matsuo K, Burda S, Yamamoto H, Yoshino N, Kaizu M, Ando S, Okuda K, Zolla-Pazner S, Yamazaki S, Yamamoto N, Honda M. 2005. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guerin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. J Virol 79:1452-1462. https://doi.org/10.1128/JVI.79.3.1452 -1462.2005.
26. Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S, Yoshino N, Sakai K, Shinohara K, Matsumoto S, Yamada T, Yamazaki S, Yamamoto N, Honda M. 2005. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J Virol 79:12871-12879. https://doi.org/10.1128/JVI.79.20.12871-12879.2005.
27. Chege GK, Burgers WA, Stutz H, Meyers AE, Chapman R, Kiravu A, Bunjun R, Shephard EG, Jacobs WR, Jr, Rybicki EP, Williamson AL. 2013. Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model. J Virol 87: 5151-5160. https://doi.org/10.1128/JVI.03178-12.
28. Yasutomi Y, Koenig S, Haun SS, Stover CK, Jackson RK, Conard P, Conley AJ, Emini EA, Fuerst TR, Letvin NL. 1993. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J Immunol 150:3101-3107.
29. Cayabyab MJ, Korioth-Schmitz B, Sun Y, Carville A, Balachandran H, Miura A, Carlson KR, Buzby AP, Haynes BF, Jacobs WR, Letvin NL. 2009. Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J Virol 83:5505-5513. https://doi.org/10.1128/JVI.02544-08.
30. Rosario M, Fulkerson J, Soneji S, Parker J, Im EJ, Borthwick N, Bridgeman A, Bourne C, Joseph J, Sadoff JC, Hanke T. 2010. Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques. J Virol 84:7815-7821. https:// doi.org/10.1128/JVI.00726-10.
31. Kleinnijenhuis J, van Crevel R, Netea MG. 2015. Trained immunity: consequences for the heterologous effects of BCG vaccination. Trans R Soc Trop Med Hyg 109:29-35. https://doi.org/10.1093/trstmh/tru168.
32. Netea MG, Latz E, Mills KH, O'Neill LA. 2015. Innate immune memory: a paradigm shift in understanding host defense. Nat Immunol 16: 675-679. https://doi.org/10.1038/ni.3178.
33. Levy O, Suter EE, Miller RL, Wessels MR. 2006. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 108:1284-1290. https://doi.org/10.1182/blood-2005-12 -4821.
34. Philbin VJ, Dowling DJ, Gallington LC, Cortes G, Tan Z, Suter EE, Chi KW, Shuckett A, Stoler-Barak L, Tomai M, Miller RL, Mansfield K, Levy O. 2012. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J Allergy Clin Immunol 130:195-204.e9. https://doi.org/10.1016/j.jaci.2012.02.042.
35. Lancet. 2007. STEP study: disappointing, but not a failure. Lancet 370: 1665. https://doi.org/10.1016/S0140-6736(07)61702-4.
36. Sekaly RP. 2008. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 205:7-12. https://doi.org/10.1084/jem.20072681.
37. Blais ME, Rowland-Jones S. 2009. Lessons from the failure of the adenovector HIV vaccine. F1000 Biol Rep 1:50. https://doi.org/10.3410/B1-50.
38. Oxford KL, Dela Pena-Ponce MG, Jensen K, Eberhardt MK, Spinner A, Van Rompay KK, Rigdon J, Mollan KR, Krishnan VV, Hudgens MG, Barry PA, De Paris K. 2015. The interplay between immune maturation, age, chronic viral infection and environment. Immun Ageing 12:3. https://doi.org/ 10.1186/s12979-015-0030-3.
39. Kirmaier A, Wu F, Newman RM, Hall LR, Morgan JS, O'Connor S, Marx PA, Meythaler M, Goldstein S, Buckler-White A, Kaur A, Hirsch VM, Johnson WE. 2010. TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol 8:e1000462. https://doi.org/10.1371/ journal.pbio.1000462.
40. Lim SY, Chan T, Gelman RS, Whitney JB, O'Brien KL, Barouch DH, Goldstein DB, Haynes BF, Letvin NL. 2010. Contributions of Mamu-A 01 status and TRIM5 allele expression, but not CCL3L copy number variation, to the control of SIVmac251 replication in Indian-origin rhesus monkeys. PLoS Genet 6:e1000997. https://doi.org/10.1371/journal.pgen.1000997.
41. Giraldo-Vela JP, Rudersdorf R, Chung C, Qi Y, Wallace LT, Bimber B, Borchardt GJ, Fisk DL, Glidden CE, Loffredo JT, Piaskowski SM, Furlott JR, Morales-Martinez JP, Wilson NA, Rehrauer WM, Lifson JD, Carrington M, Watkins DI. 2008. The major histocompatibility complex class II alleles Mamu-DRB1∗1003 and -DRB1∗0306 are enriched in a cohort of simian immunodeficiency virus-infected rhesus macaque elite controllers. J Virol 82:859-870. https://doi.org/10.1128/JVI.01816-07.
42. Loffredo JT, Sidney J, Piaskowski S, Szymanski A, Furlott J, Rudersdorf R, Reed J, Peters B, Hickman-Miller HD, Bardet W, Rehrauer WM, O'Connor DH, Wilson NA, Hildebrand WH, Sette A, Watkins DI. 2005. The high frequency Indian rhesus macaque MHC class I molecule, Mamu-B∗01, does not appear to be involved in CD8+ T lymphocyte responses to SIVmac239. J Immunol 175:5986-5997. https://doi.org/10.4049/ jimmunol.175.9.5986.
43. Evans DT, Knapp LA, Jing P, Mitchen JL, Dykhuizen M, Montefiori DC, Pauza CD, Watkins DI. 1999. Rapid and slow progressors differ by a single MHC class I haplotype in a family of MHC-defined rhesus macaques infected with SIV. Immunol Lett 66:53-59. https://doi.org/10.1016/S0165 -2478(98)00151-5.
44. Muhl T, Krawczak M, Ten Haaft P, Hunsmann G, Sauermann U. 2002. MHC class I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys. J Immunol 169:3438-3446. https://doi.org/10.4049/jimmunol.169.6.3438.
45. Mothe BR, Weinfurter J, Wang C, Rehrauer W, Wilson N, Allen TM, Allison DB, Watkins DI. 2003. Expression of the major histocompatibility complex class I molecule Mamu-A01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 77:2736-2740. https://doi.org/10.1128/JVI.77.4.2736-2740.2003.
46. O'Connor DH, Mothe BR, Weinfurter JT, Fuenger S, Rehrauer WM, Jing P, Rudersdorf RR, Liebl ME, Krebs K, Vasquez J, Dodds E, Loffredo J, Martin S, McDermott AB, Allen TM, Wang C, Doxiadis GG, Montefiori DC, Hughes A, Burton DR, Allison DB, Wolinsky SM, Bontrop R, Picker LJ, Watkins DI. 2003. Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. J Virol 77:9029-9040. https://doi.org/10.1128/JVI.77.16.9029 -9040.2003.
47. Fenizia C, Keele BF, Nichols D, Cornara S, Binello N, Vaccari M, Pegu P, Robert-Guroff M, Ma ZM, Miller CJ, Venzon D, Hirsch V, Franchini G. 2011. TRIM5alpha does not affect simian immunodeficiency virus SIV(mac251) replication in vaccinated or unvaccinated Indian rhesus macaques following intrarectal challenge exposure. J Virol 85:12399-12409. https:// doi.org/10.1128/JVI.05707-11.
48. Ancuta P, Autissier P, Wurcel A, Zaman T, Stone D, Gabuzda D. 2006. CD16 monocyte-derived macrophages activate resting T cells for HIV infection by producing CCR3 and CCR4 ligands. J Immunol 176: 5760-5771. https://doi.org/10.4049/jimmunol.176.10.5760.
49. Kim WK, Sun Y, Do H, Autissier P, Halpern EF, Piatak M, Jr, Lifson JD, Burdo TH, McGrath MS, Williams K. 2010. Monocyte heterogeneity underlying phenotypic changes in monocytes according to SIV disease stage. J Leukoc Biol 87:557-567. https://doi.org/10.1189/jlb.0209082.
50. Netea MG, Joosten LA, van der Meer JW, Kullberg BJ, van de Veerdonk FL. 2015. Immune defence against Candida fungal infections. Nat Rev Immunol 15:630-642. https://doi.org/10.1038/nri3897.
51. Thysen SM, Aaby P, Benn CS, Fisker AB. 2015. Changes in BCG vaccination policy should consider the effect on child health. J Infect Dis 212:1341-1342. https://doi.org/10.1093/infdis/jiv198.
52. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Jacobs C, Xavier RJ, van der Meer JW, van Crevel R, Netea MG. 2014. BCG-induced trained immunity in NK cells: role for non-specific protection to infection. Clin Immunol 155:213-219. https://doi.org/10.1016/j.clim.2014.10.005.
53. Levy O, Levy O. 2015. Ready to benefit from training: heterologous effects of early life immunization. Trans R Soc Trop Med Hyg 109:3-4. https//doi.org/10.1093/trstmh/tru185.
54. Benn CS, Netea MG, Selin LK, Aaby P. 2013. A small jab -a big effect: nonspecific immunomodulation by vaccines. Trends Immunol 34: 431-439. https://doi.org/10.1016/j.it.2013.04.004.
55. Kaufmann SH, Cotton MF, Eisele B, Gengenbacher M, Grode L, Hesseling AC, Walzl G. 2014. The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Rev Vaccines 13:619-630. https:// doi.org/10.1586/14760584.2014.905746.
56. Arbues A, Aguilo JI, Gonzalo-Asensio J, Marinova D, Uranga S, Puentes E, Fernandez C, Parra A, Cardona PJ, Vilaplana C, Ausina V, Williams A, Clark S, Malaga W, Guilhot C, Gicquel B, Martin C. 2013. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. Tuberculosis-based vaccine to enter clinical trials. Vaccine 31: 4867-4873. https://doi.org/10.1016/j.vaccine.2013.07.051.
57. Jain P, Hsu T, Arai M, Biermann K, Thaler DS, Nguyen A, Gonzalez PA, Tufariello JM, Kriakov J, Chen B, Larsen MH, Jacobs WR, Jr. 2014. Specialized transduction designed for precise high-throughput unmarked deletions in Mycobacterium tuberculosis. mBio 5:e01245-14. https:// doi.org/10.1128/mBio.01245-14.
58. Jensen KJ, Larsen N, Biering-Sorensen S, Andersen A, Eriksen HB, Monteiro I, Hougaard D, Aaby P, Netea MG, Flanagan KL, Benn CS. 2015. Heterologous immunological effects of early BCG vaccination in lowbirth-weight infants in Guinea-Bissau: a randomized-controlled trial. J Infect Dis 211:956-967. https://doi.org/10.1093/infdis/jiu508.
59. Kahle EM, Bolton M, Hughes JP, Donnell D, Celum C, Lingappa JR, Ronald A, Cohen CR, de Bruyn G, Fong Y, Katabira E, McElrath MJ, Baeten JM, Partners in Prevention HSV/HIV Transmission Study Team. 2015. Plasma cytokine levels and risk of HIV type 1 (HIV-1) transmission and acquisition: a nested case-control study among HIV-1-serodiscordant couples. J Infect Dis 211:1451-1460. https://doi.org/10.1093/infdis/ jiu621.
60. Lehmann S, Relano-Gines A, Resina S, Brillaud E, Casanova D, Vincent C, Hamela C, Poupeau S, Laffont M, Gabelle A, Delaby C, Belondrade M, Arnaud JD, Alvarez MT, Maurel JC, Maurel P, Crozet C. 2014. Systemic delivery of siRNA down regulates brain prion protein and ameliorates neuropathology in prion disorder. PLoS One 9:e88797. https://doi.org/ 10.1371/journal.pone.0088797.
61. Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, Sibeko S, Abdool Karim Q, Carr WH, CAPRISA004 TRAPS Team. 2012. Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis 206: 993-1001. https://doi.org/10.1093/infdis/jis465.
62. Qureshi H, Genesca M, Fritts L, McChesney MB, Robert-Guroff M, Miller CJ. 2014. Infection with host-range mutant adenovirus 5 suppresses innate immunity and induces systemic CD4+ T cell activation in rhesus macaques. PLoS One 9:e106004. https://doi.org/10.1371/journal .pone.0106004.
63. Huang Y, Duerr A, Frahm N, Zhang L, Moodie Z, De Rosa S, McElrath MJ, Gilbert PB. 2014. Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-gamma secretion with increased HIV-1 infection risk: a cohort-based modeling study. PLoS One 9:e108631. https://doi.org/10.1371/journal.pone.0108631.
64. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB, HVTN 505 Study Team. 2013. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 369:2083-2092. https://doi.org/10.1056/NEJMoa1310566.
65. Marthas ML, Van Rompay KK, Abbott Z, Earl P, Buonocore-Buzzelli L, Moss B, Rose NF, Rose JK, Kozlowski PA, Abel K. 2011. Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. Vaccine 29:3124-3137. https://doi.org/10.1016/j.vaccine .2011.02.051.
66. Xiao P, Patterson LJ, Kuate S, Brocca-Cofano E, Thomas MA, Venzon D, Zhao J, DiPasquale J, Fenizia C, Lee EM, Kalisz I, Kalyanaraman VS, Pal R, Montefiori D, Keele BF, Robert-Guroff M. 2012. Replicating adenovirussimian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated lowdose rectal SIV(mac251) challenge. J Virol 86:4644-4657. https://doi.org/ 10.1128/JVI.06812-11.
67. Sun Y, Bailer RT, Rao SS, Mascola JR, Nabel GJ, Koup RA, Letvin NL. 2009. Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys. J Virol 83:10596-10604. https:// doi.org/10.1128/JVI.01170-09.
68. Benlahrech A, Harris J, Meiser A, Papagatsias T, Hornig J, Hayes P, Lieber A, Athanasopoulos T, Bachy V, Csomor E, Daniels R, Fisher K, Gotch F, Seymour L, Logan K, Barbagallo R, Klavinskis L, Dickson G, Patterson S. 2009. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci U S A 106:19940-19945. https://doi.org/ 10.1073/pnas.0907898106.
69. Chakupurakal G, Onion D, Cobbold M, Mautner V, Moss PA. 2010. Adenovirus vector-specific T cells demonstrate a unique memory phenotype with high proliferative potential and coexpression of CCR5 and integrin alpha4beta7. AIDS 24:205-210. https://doi.org/10.1097/ QAD.0b013e328333addf.
70. O'Brien KL, Liu J, King SL, Sun YH, Schmitz JE, Lifton MA, Hutnick NA, Betts MR, Dubey SA, Goudsmit J, Shiver JW, Robertson MN, Casimiro DR, Barouch DH. 2009. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 15:873-875. https://doi.org/10.1038/nm.1991.
71. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR, Step Study Protocol Team. 2008. HIV-1 vaccine-induced immunity in the test-ofconcept Step Study: a case-cohort analysis. Lancet 372:1894-1905. https://doi.org/10.1016/S0140-6736(08)61592-5.
72. Tenbusch M, Ignatius R, Temchura V, Nabi G, Tippler B, Stewart-Jones G, Salazar AM, Sauermann U, Stahl-Hennig C, Uberla K. 2012. Risk of immunodeficiency virus infection may increase with vaccine-induced immune response. J Virol 86:10533-10539. https://doi.org/10.1128/ JVI.00796-12.
73. Carnathan DG, Wetzel KS, Yu J, Lee ST, Johnson BA, Paiardini M, Yan J, Morrow MP, Sardesai NY, Weiner DB, Ertl HC, Silvestri G. 2015. Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques. Proc Natl Acad Sci U S A 112:518-523. https://doi.org/10.1073/pnas.1407466112.
74. Sui Y, Lee EM, Wang Y, Hogg A, Frey B, Venzon D, Pal R, Berzofsky JA. 2016. Early SIV dissemination after intrarectal SIVmac251 challenge was associated with proliferating virus-susceptible cells in the colorectum. J Acquir Immune Defic Syndr 71:353-358. https://doi.org/10.1097/ QAI.0000000000000890.
75. Thayil SM, Ho YC, Bollinger RC, Blankson JN, Siliciano RF, Karakousis PC, Page KR. 2012. Mycobacterium tuberculosis complex enhances susceptibility of CD4 T cells to HIV through a TLR2-mediated pathway. PLoS One 7:e41093. https://doi.org/10.1371/journal.pone.0041093.
76. Ding J, Rapista A, Teleshova N, Mosoyan G, Jarvis GA, Klotman ME, Chang TL. 2010. Neisseria gonorrhoeae enhances HIV-1 infection of primary resting CD4+ T cells through TLR2 activation. J Immunol 184: 2814-2824. https://doi.org/10.4049/jimmunol.0902125.
77. Thibault S, Tardif MR, Barat C, Tremblay MJ. 2007. TLR2 signaling renders quiescent naive and memory CD4+ T cells more susceptible to productive infection with X4 and R5 HIV-type 1. J Immunol 179:4357-4366. https//doi.org/10.4049/jimmunol.179.7.4357.
78. Skerry C, Klinkenberg LG, Page KR, Karakousis PC. 2016. TLR2-modulating lipoproteins of the Mycobacterium tuberculosis complex enhance the HIV infectivity of CD4+ T cells. PLoS One 11:e0147192. https://doi.org/10.1371/journal.pone.0147192.
79. Mishra G, Poojary SS, Raj P, Tiwari PK. 2012. Genetic polymorphisms of CCL2, CCL5, CCR2 and CCR5 genes in Sahariya tribe of North Central India: an association study with pulmonary tuberculosis. Infect Genet Evol 12:1120-1127. https://doi.org/10.1016/j.meegid.2012.03.018.
80. Chen Z, Wang W, Liang J, Wang J, Feng S, Zhang G. 2015. Association between Toll-like receptors 9 (TLR9) gene polymorphism and risk of pulmonary tuberculosis: meta-analysis. BMC Pulm Med 15:57. https:// doi.org/10.1186/s12890-015-0049-4.
81. Bulat-Kardum LJ, Etokebe GE, Lederer P, Balen S, Dembic Z. 2015. Genetic polymorphisms in the Toll-like receptor 10, interleukin (IL)17A and IL17F genes differently affect the risk for tuberculosis in Croatian population. Scand J Immunol 82:63-69. https//doi.org/10.1111/ sji.12300.
82. Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E, Darboe F, Penn-Nicholson A, Nemes E, Hatheril M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H. 2016. T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nat Commun 7:11290. https://doi.org/ 10.1038/ncomms11290.
83. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
84. Earl PL, Wyatt LS, Montefiori DC, Bilska M, Woodward R, Markham PD, Malley JD, Vogel TU, Allen TM, Watkins DI, Miller N, Moss B. 2002. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology 294:270-281. https://doi.org/10.1006/ viro.2001.1345.
85. Van Rompay KK, Abel K, Lawson JR, Singh RP, Schmidt KA, Evans T, Earl P, Harvey D, Franchini G, Tartaglia J, Montefiori D, Hattangadi S, Moss B, Marthas ML. 2005. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr 38:124-134. https://doi.org/10.1097/00126334 -200502010-00002.
86. Winstone N, Wilson AJ, Morrow G, Boggiano C, Chiuchiolo MJ, Lopez M, Kemelman M, Ginsberg AA, Mullen K, Coleman JW, Wu CD, Narpala S, Ouellette I, Dean HJ, Lin F, Sardesai NY, Cassamasa H, McBride D, Felber BK, Pavlakis GN, Schultz A, Hudgens MG, King CR, Zamb TJ, Parks CL, McDermott AB. 2011. Enhanced control of pathogenic simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. J Virol 85:9578-9587. https://doi.org/10.1128/JVI.05060-11.
87. Van Rompay KK, Singh RP, Brignolo LL, Lawson JR, Schmidt KA, Pahar B, Canfield DR, Tarara RP, Sodora DL, Bischofberger N, Marthas ML. 2004. The clinical benefits of tenofovir for simian immunodeficiency virusinfected macaques are larger than predicted by its effects on standard viral and immunologic parameters. J Acquir Immune Defic Syndr 36: 900-914. https://doi.org/10.1097/00126334-200408010-00003.
88. Li H, Wang S, Kong R, Ding W, Lee FH, Parker Z, Kim E, Learn GH, Hahn P, Policicchio B, Brocca-Cofano E, Deleage C, Hao X, Chuang GY, Gorman J, Gardner M, Lewis MG, Hatziioannou T, Santra S, Apetrei C, Pandrea I, Alam SM, Liao HX, Shen X, Tomaras GD, Farzan M, Chertova E, Keele BF, Estes JD, Lifson JD, Doms RW, Montefiori DC, Haynes BF, Sodroski JG, Kwong PD, Hahn BH, Shaw GM. 2016. Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc Natl Acad Sci U S A 113: E3413-E3422. https://doi.org/10.1073/pnas.1606636113.
89. Kaizu M, Borchardt GJ, Glidden CE, Fisk DL, Loffredo JT, Watkins DI, Rehrauer WM. 2007. Molecular typing of major histocompatibility complex class I alleles in the Indian rhesus macaque which restrict SIV CD8+ T cell epitopes. Immunogenetics 59:693-703. https://doi.org/10.1007/ s00251-007-0233-7.
90. Loffredo JT, Friedrich TC, Leon EJ, Stephany JJ, Rodrigues DS, Spencer SP, Bean AT, Beal DR, Burwitz BJ, Rudersdorf RA, Wallace LT, Piaskowski SM, May GE, Sidney J, Gostick E, Wilson NA, Price DA, Kallas EG, Piontkivska H, Hughes AL, Sette A, Watkins DI. 2007. CD8+ T cells from SIV elite controller macaques recognize Mamu-B∗08-bound epitopes and select for widespread viral variation. PLoS One 2:e1152. https://doi.org/ 10.1371/journal.pone.0001152.
91. Loffredo JT, Maxwell J, Qi Y, Glidden CE, Borchardt GJ, Soma T, Bean AT, Beal DR, Wilson NA, Rehrauer WM, Lifson JD, Carrington M, Watkins DI. 2007. Mamu-B 8-positive macaques control simian immunodeficiency virus replication. J Virol 81:8827-8832. https://doi.org/10.1128/JVI.00895-07.
92. Yant LJ, Friedrich TC, Johnson RC, May GE, Maness NJ, Enz AM, Lifson JD, O'Connor DH, Carrington M, Watkins DI. 2006. The high-frequency major histocompatibility complex class I allele Mamu-B 17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 80:5074-5077. https://doi.org/10.1128/JVI.80.10.5074-5077.2006.
93. Canary LA, Vinton CL, Morcock DR, Pierce JB, Estes JD, Brenchley JM, Klatt NR. 2013. Rate of AIDS progression is associated with gastrointestinal dysfunction in simian immunodeficiency virus-infected pigtail macaques. J Immunol 190:2959-2965. https://doi.org/10.4049/ jimmunol.1202319.
94. Estes JD, Harris LD, Klatt NR, Tabb B, Pittaluga S, Paiardini M, Barclay GR, Smedley J, Pung R, Oliveira KM, Hirsch VM, Silvestri G, Douek DC, Miller CJ, Haase AT, Lifson J, Brenchley JM. 2010. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog 6:e1001052. https://doi.org/ 10.1371/journal.ppat.1001052.
95. Somsouk M, Estes JD, Deleage C, Dunham RM, Albright R, Inadomi JM, Martin JN, Deeks SG, McCune JM, Hunt PW. 2015. Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS 29:43-51. https://doi.org/10.1097/QAD.0000000000000511.
96. Tabb B, Morcock DR, Trubey CM, Quinones OA, Hao XP, Smedley J, Macallister R, Piatak M, Jr, Harris LD, Paiardini M, Silvestri G, Brenchley JM, Alvord WG, Lifson JD, Estes JD. 2013. Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving antitumor necrosis factor treatment during primary simian immunodeficiency virus infection. J Infect Dis 207:880-892. https://doi.org/10.1093/ infdis/jis643.